Sleep disturbance among Malaysian patients with end-stage renal disease with pruritus

Rehman, Inayat Ur; Lai, Pauline Siew Mei; Lim, Soo Kun; Lee, Learn‐Han; Khan, Tahir Mehmood

doi:10.1186/s12882-019-1294-1

Cited by 20 publications

(21 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a 2019 study published by Rehman et al, the prevalence of pruritus was 61.4%. 15 In a 2010 study by Martinez M. A. et al, the prevalence of half and half nails was 14.4%. 16 Also, in the study by Jamal A. in 2000, the prevalence of half and half nails in patients undergoing hemodialysis was 26%.…”

Section: Discussionmentioning

confidence: 95%

Mucocutaneous manifestations of patients with chronic kidney disease under hemodialysis: A cross‐sectional study of 49 patients

Tajalli

Mirahmadi

Mozafarpoor

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a common medical problem with well-known dermatologic manifestations, some of which highly disturb the patients' quality of life. This cross-sectional study was designed to identify the prevalence and type of cutaneous involvement in CKD patients. The skin manifestations of 49 patients with CKD undergoing hemodialysis at Akhavan Hospital in Kashan, Iran, were recorded over 2 months. Diabetes (35%) was the most common cause of chronic renal failure in the patients, and the most common skin manifestations were xerosis (95.9%), uremic pigmentation (89.8%), scleral discoloration (87.8%), dental discoloration (85.2% among the patients with natural teeth), dry mouth (65.3%), varicosity (61.2%), pruritus (57.1%), skin atrophy (49%), lentigo (46.9%), subungual hyperkeratosis (42.9%), half and half nail dystrophy (34.7%), and purpura (26.5%). Mucocutaneous involvement has a very high prevalence in CKD patients undergoing hemodialysis, and some of the cases are medically and cosmetically disturbing; therefore, with better knowledge about the type and prevalence of these involvements, the consequences can be better predicted and managed. Further studies are recommended to be conducted on the association between these signs and CKD grade, and clinical trials are also required for establishing the treatment options available for these signs and then assessing the patients' quality of life as a primary outcome measure.

show abstract

Section: Discussionmentioning

confidence: 95%

Mucocutaneous manifestations of patients with chronic kidney disease under hemodialysis: A cross‐sectional study of 49 patients

Tajalli

Mirahmadi

Mozafarpoor

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…These results are higher than those found in previous research in patients receiving haemodialysis. Including fatigue (47%) [ 17 ], anxiety (17.5%) [ 18 ], depression (28%) [ 19 ] and sleep quality (48%) [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Fatigue, anxiety, depression and sleep quality in patients undergoing haemodialysis

et al. 2021

View full text Add to dashboard Cite

Objective Patients undergoing haemodialysis may experience troubling symptoms such as fatigue, anxiety, depression and sleep quality, which may affect their quality of life. The main objective of this study is to determine the prevalence of fatigue, anxiety, depression and sleep quality among patients receiving haemodialysis during the coronavirus disease 2019 (COVID-19) pandemic, and to explore the contributing predictors. Methods A cross-sectional and descriptive correlational design using Qualtrics software was performed. Data were collected using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F), the Hospital Anxiety and Depression Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI). Logistic regression analyses were used to explore the predictors that were associated with fatigue, anxiety, depression and sleep quality. Results Of the 123 patients undergoing haemodialysis who participated, 53.7% (n = 66) reported fatigue, 43.9% (n = 54) reported anxiety, 33.3% (n = 41) reported depression and 56.9% (n = 70) reported poor sleep. Fatigue, anxiety and sleep quality (P < .05) were significantly associated with being female, and whether family members or relatives were suspected or confirmed with COVID-19. Logistic regression showed that being within the age group 31–40, having a secondary education level, anxiety, depression and sleep quality were the main predictors affecting the fatigue group. Conclusion Fatigue, anxiety, depression and sleep quality are significant problems for patients receiving haemodialysis during the COVID-19 pandemic. Appropriate interventions to monitor and reduce fatigue, psychological problems and sleep quality amongst these patients are needed. This can help to strengthen preparations for responding to possible future outbreaks or pandemics of infectious diseases for patients receiving haemodialysis.

show abstract

“…Of these patients, 33.1% were prescribed a sleeping pill. A Malaysian study of 334 HD patients found a 5.47-fold increased risk of poor sleep quality in patients with moderate to severe pruritus compared with those with mild or no itch [ 43 ]. These findings are similarly noted in PD patients, with increased sleep disorders associated with increased severity of itch [ 14 ].…”

Section: Impact Of Ckd-ap On Health-related Qol (Hrqol) and Medical Outcomesmentioning

confidence: 99%

Epidemiology and burden of chronic kidney disease-associated pruritus

Kim

Pollock

2021

Clinical Kidney Journal

View full text Add to dashboard Cite

Chronic kidney disease–associated pruritus (CKD-aP) is a common, yet underrecognized condition in patients with CKD and end-stage kidney disease (ESKD). Real-world observational studies indicate that CKD-aP affects up to 80% of ESKD patients undergoing haemodialysis (HD), with ∼40% experiencing moderate to severe itch. CKD-aP can negatively impact patients’ mental and physical health-related quality of life (HRQoL) and is also associated with sleep disturbance and depression. Several studies have found that CKD-aP is a predictor of adverse medical outcomes, including an increased risk of hospitalizations and mortality. In this article we review the literature relating to the epidemiology of CKD-aP to describe its prevalence across the treatment spectrum of CKD (non-dialysis, HD, peritoneal dialysis and transplant recipients) and to summarize potential risk factors associated with its development. We also review key data from studies that have evaluated the impact of CKD-aP on HRQoL and medical outcomes.

show abstract

Sleep disturbance among Malaysian patients with end-stage renal disease with pruritus

Cited by 20 publications

References 45 publications

Mucocutaneous manifestations of patients with chronic kidney disease under hemodialysis: A cross‐sectional study of 49 patients

Mucocutaneous manifestations of patients with chronic kidney disease under hemodialysis: A cross‐sectional study of 49 patients

Fatigue, anxiety, depression and sleep quality in patients undergoing haemodialysis

Epidemiology and burden of chronic kidney disease-associated pruritus

Contact Info

Product

Resources

About